|
| Betaadrenergic signaling a novel target for cancer therapy |
|
https://doi.org/10.18632/oncotarget.182
Hildegard M. Schuller
|
| 466-469 |
|
| A new therapeutic basis for treating LiFraumeni Syndrome breast tumors expressing mutated TP53 |
|
https://doi.org/10.18632/oncotarget.183
Robert I. Glazer
|
| 470-471 |
|
| Refractory chronic lymphocytic leukemia – new therapeutic strategies |
|
https://doi.org/10.18632/oncotarget.184
Andrea Schnaiter, and Stephan Stilgenbauer
|
| 472-482 |
|
| Standards and Impact of Hematopathology in Myelodysplastic Syndromes MDS |
|
https://doi.org/10.18632/oncotarget.185
Peter Valent, Attilio Orazi, Guntram Büsche, Annette Schmitt-Gräff, Tracy I. George, Karl Sotlar, Berthold Streubel, Christine Beham-Schmid, Sabine Cerny-Reiterer, Otto Krieger, Arjan van de Loosdrecht, Wolfgang Kern, Kiyoyuki Ogata, Friedrich Wimazal, Judit Csomor, Judit Várkonyi, Wolfgang R. Sperr, Martin Werner, Hans Kreipe, and Hans-Peter Horny
|
| 483-496 |
|
| EGFRmutated lung cancer: a paradigm of molecular oncology |
|
https://doi.org/10.18632/oncotarget.186
Zhenfeng Zhang, Amy L. Stiegler, Titus J. Boggon, Susumu Kobayashi, and Balazs Halmos
|
| 497-514 |
|
| Antiangiogenic agents in advanced gastrointestinal malignancies: past present and a novel future |
|
https://doi.org/10.18632/oncotarget.187
Karen Mulder, Sheryl Koski, Andrew Scarfe, Quincy Chu, Karen King, and Jennifer Spratlin
|
| 515-529 |
|
| Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs |
|
https://doi.org/10.18632/oncotarget.188
Ben Markman, Rodrigo Dienstmann, and Josep Tabernero
|
| 530-543 |
|
| The pursuit of oncotargets through understanding defective cell regulation |
|
https://doi.org/10.18632/oncotarget.189
Meng Qiao, Qian Shi, and Arthur B. Pardee
|
| 544-551 |
|
| Targeting Metabolic Remodeling in Glioblastoma Multiforme |
|
https://doi.org/10.18632/oncotarget.190
Amparo Wolf, Sameer Agnihotri, and Abhijit Guha
|
| 552-562 |
|
| Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells |
|
https://doi.org/10.18632/oncotarget.191
Joshua C. Curtin, and Matthew V. Lorenzi
|
| 563-577 |
|
| Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia |
|
https://doi.org/10.18632/oncotarget.192
Antonio Sacco, Aldo Roccaro, and Irene M. Ghobrial
|
| 578-582 |
|
| The requirement of p53 for maintaining chromosomal stability during tetraploidization |
|
https://doi.org/10.18632/oncotarget.193
Chui Chui Ho, Pok Man Hau, Miriam Marxer, and Randy Y.C. Poon
|
| 583-595 |
|
| The Class I Hdac Inhibitor Mgcd0103 Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Initiating Cells by Upregulating Dickkopf1 and NonCanonical Wnt Signaling |
|
https://doi.org/10.18632/oncotarget.194
Shaheen Sikandar, Diana Dizon, Xiling Shen, Zuomei Li, Jeffery Besterman, and Steven M. Lipkin
|
| 596-605 |
|
| Homologous recombination repair is essential for repair of vosaroxininduced DNA doublestrand breaks |
|
https://doi.org/10.18632/oncotarget.195
Rachael Elizabeth Hawtin, David Elliot Stockett, Oi Kwan Wong, Cecilia Lundin, Thomas Helleday, and Judith Ann Fox
|
| 606-619 |
|
| Sumoylation of Vimentin354 Is Associated with PIAS3 Inhibition of Glioma Cell Migration |
|
https://doi.org/10.18632/oncotarget.196
Liming Wang, Jian Zhang, Sipra Banerjee, Laura Barnes, Venkateswara Sajja, Yiding Liu, Baochuan Guo, Yuping Du, Mukesh K. Agarwal, David N. Wald, Qin Wang, and Jinbo Yang
|
| 620-627 |
|
| BetaBlocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival |
|
https://doi.org/10.18632/oncotarget.197
Desmond G. Powe, Melanie J. Voss, Kurt S. Zänker, Hany O. Habashy, Andrew R. Green, Ian O. Ellis, and Frank Entschladen
|
| 628-638 |
|
| Evaluation of an Actinomycin D/VX680 aurora kinase inhibitor combination in p53based cyclotherapy |
|
https://doi.org/10.18632/oncotarget.198
Bhavya Rao, Ingeborg M.M. van Leeuwen, Maureen Higgins, Johanna Campbell, Alastair M. Thompson, David P. Lane, and Sonia Lain
|
| 639-650 |
|
| Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget |
|
https://doi.org/10.18632/oncotarget.199
Inti Zlobec, and Alessandro Lugli
|
| 651-661 |
|
| Targeting tumor angiogenesis with TSP1based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors |
|
https://doi.org/10.18632/oncotarget.200
Giulia Taraboletti, Marco Rusnati, Laura Ragona, and Giorgio Colombo
|
| 662-673 |
|
| Wnt/Î’Catenin and Sex Hormone Signaling In Endometrial Homeostasis and Cancer |
|
https://doi.org/10.18632/oncotarget.201
Yongyi Wang, Marten van der Zee, Riccardo Fodde, and Leen J. Blok
|
| 674-684 |
|
| Novel Insights into the Molecular Mechanisms Governing Mdm2 Ubiquitination and Destruction |
|
https://doi.org/10.18632/oncotarget.202
Hiroyuki Inuzuka, Hidefumi Fukushima, Shavali Shaik, and Wenyi Wei
|
| 685-690 |
